5-Amino-1MQ
An NNMT inhibitor that targets white adipose tissue to increase metabolism and reduce fat.
Common Dosage
50mg - 150mg oral daily
Category
Metabolic
- Fat loss
- Muscle preservation
- Cellular energy
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor developed through collaboration between research groups studying adipose tissue metabolism. NNMT was identified as an enzyme that becomes overexpressed in white adipose tissue during obesity, contributing to a 'metabolic sink' that reduces cellular NAD+ availability and impairs metabolism. Inhibiting NNMT with 5-Amino-1MQ was proposed as a way to restore normal adipose tissue metabolic activity.
NNMT methylates nicotinamide, effectively sequestering methyl groups and reducing NAD+ synthesis from this precursor in adipose tissue. 5-Amino-1MQ inhibits this enzyme, increasing NAD+ availability in fat cells, activating sirtuin pathways, and shifting white adipose tissue from a storage-dominant to a metabolism-dominant phenotype. It does not appear to have systemic sympathomimetic effects, distinguishing it from traditional stimulant-based fat burners.
- Targeted white adipose tissue metabolism improvement
- Fat loss without muscle catabolism
- Insulin sensitivity improvement
- Metabolic syndrome management
Adipose-Specific Fat Reduction
Animal studies have demonstrated selective reductions in white adipose tissue mass without affecting lean muscle mass or causing the thermogenic stress seen with stimulant fat burners. The NNMT inhibition specifically targets fat cell metabolic dysfunction.
- Human clinical data is absent — preclinical compound
- NNMT has roles beyond adipose tissue — methyl group metabolism has broad genomic effects through methylation reactions
- Oral bioavailability and dosing in humans is not established
- Long-term effects on NAD+ metabolism system-wide are unknown
- None reported commonly